Zevra Therapeutics stockholders elect Dixon and Favorito as Class I directors

ZEVRA THERAPEUTICS, INC.

Wendy Dixon elected with 25.8M for (9.1M withheld); Tamara Favorito with 25.6M for (9.3M withheld). Broker non-votes ~9.65M.
Dissident Mangless failed to comply with Rule 14a-19 and bylaws; his nominees Mickle and Regan disregarded despite 9.2M and 8.4M votes.
Ratification of Ernst & Young as auditor passed: 43.8M for, 360k against, 382k abstain; no broker non-votes.
81.4% of outstanding shares (44.5M of 54.7M) were present or represented at the May 29, 2025 meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.